The FDA and RSF will have had the dosing information from the Nuereen "trofinetide" P2 trial which will have gone thru a similar assessment as 2-73 dosing has gone thru. Participant age and body size is being taken into consideration. This may vary drastically depending on the enrollees. In the "trofinetide" trial age ran up to 45.
Market Data 
Markets 
AI
